Efficacy of a glucose meter connected to a mobile app on glycemic control and adherence to self-care tasks in patients with T1DM and LADA: a parallel-group, open-label, clinical treatment trial
Authors:
- Felipe Martins de OliveiraFOFelipe Martins de Oliveira
- Luís Eduardo Procópio CalliariLCLuís Eduardo Procópio Calliari
- Cecília Kauffman Rutenberg FederCFCecília Kauffman Rutenberg Feder
- Maria Fernanda Ozorio de AlmeidaMAMaria Fernanda Ozorio de Almeida
- Mariana Vilela PereiraMPMariana Vilela Pereira
- Maria Thereza Teixeira de Almeida Fagundes AlvesMAMaria Thereza Teixeira de Almeida Fagundes Alves
- Sônia Aparecida Dias GarciaSGSônia Aparecida Dias Garcia
- Ligia Dinara Donizeti ReisLRLigia Dinara Donizeti Reis
- João Eduardo Nunes SallesJSJoão Eduardo Nunes Salles
Open Access
- 25 February 2021
- journal article
- research article
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 65 (AHEAD) , 185-197
Abstract
Y Objective: The main aim of the study was to evaluate the patients' glycemic control and adherence to self-care tasks. Materials and methods: Patients with type 1 diabetes mellitus (T1DM) or latent autoimmune diabetes of the adult (LADA) using a multiple daily injection (MDI) regimen with carbohydrate counting (n = 25, Subgroup B) or fixed insulin dose (n = 25, Subgroup C) were allocated to use the application (app) for 12 weeks. Both subgroups were compared with each other and against a control group (n = 25, Group A) comprising patients with T1DM or LADA treated with continuous subcutaneous insulin infusion (CSII) in a parallel-group, open-label, clinical treatment trial. All patients had glycated hemoglobin (A1C) levels measured and were asked to fill out the Diabetes Self-Management Profile (DSMP) questionnaire at study start and end. The patients were instructed to measure capillary glucose six times daily in study weeks 4, 8, and 12. Results: Mean A1C levels decreased 0.725% in Subgroup C in intragroup analysis (p = 0.0063), and had a mean variation of 0.834% compared with Group A (p = 0.003). Mean DSMP scores increased 5.77 points in Subgroup B in intragroup analysis (p = 0.0004) and increased by a mean of 6.815 points in relation to Group A (p = 0.002). Conclusion: OneTouch Reveal improved both A1C levels and DSMP scores in patients with T1DM or LADA compared with standard treatment (CSII).Keywords
This publication has 19 references indexed in Scilit:
- An Expert Opinion on Advanced Insulin Pump Use in Youth with Type 1 DiabetesDiabetes Technology & Therapeutics, 2017
- Improving diabetes medication adherence: successful, scalable interventionsPatient Preference and Adherence, 2015
- Cross-cultural adaptation and validation to Brazilian Portuguese of two measuring adherence instruments for patients with type 1 diabetesDiabetology & Metabolic Syndrome, 2014
- A systematic literature review of methodologies used to assess medication adherence in patients with diabetesCurrent Medical Research and Opinion, 2014
- Medication Adherence in Patients with Diabetes and Dyslipidemia: Associated Factors and Strategies for ImprovementCurrent Cardiology Reports, 2013
- Real‐world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic reviewDiabetic Medicine, 2013
- Assessing Regimen Adherence of Adolescents With Type 1 DiabetesDiabetes Care, 2006
- Improving Patient AdherenceClinical Diabetes, 2006
- Adherence to Treatment: The Key for Avoiding Long-Term Complications of DiabetesArchives of Medical Research, 2005
- Validation of a structured interview for the assessment of diabetes self-management.Diabetes Care, 2000